VINC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States...

Stats
Šios dienos apimtis	1.72M
Vidutinė apimtis	1.18M
Rinkos kapitalizacija	15.63M
EPS	$0 ( 2024-03-26 )
Kita pelno data	( $-0.260 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.0120 (1.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Izumi Raquel E.	Buy	123 750	Stock Option (right to buy)
2024-03-07	Seelenberger Alexander A.	Buy	93 750	Stock Option (right to buy)
2024-03-07	Hamdy Ahmed Md	Buy	146 746	Stock Option (right to buy)
2024-03-07	Thomas Tom C	Buy	93 750	Stock Option (right to buy)
2023-08-11	Seelenberger Alexander A.	Buy	10 500	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 7 261 732 \| Sell: 1 766 942

Tūris Koreliacija

Ilgas: -0.44 (neutral)

Trumpas: -0.91 (very strong negative)

Signal:(31.431) Neutral

Vincerx Pharma, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVAC	0.929
PAIC	0.909
RMRM	0.901
TLGT	0.894
MTSL	0.893
SVOK	0.862
MODV	0.861
CLMT	0.858
BOXL	0.842
ABNB	0.839

10 Labiausiai neigiamai susiję koreliacijos
AMRB	-0.955
NETE	-0.938
MMAC	-0.917
RAVN	-0.869
SRAC	-0.86
SBBP	-0.859
LWAC	-0.855
MGPI	-0.841
BOCH	-0.836
SHSP	-0.808

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Vincerx Pharma, Inc. Koreliacija - Valiuta/Žaliavos

-0.72
( moderate negative )

-0.71
( moderate negative )

0.00
( neutral )

-0.74
( moderate negative )

0.00
( neutral )

0.02
( neutral )

Vincerx Pharma, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-915 000 (0.00 %)
EPS:	$-1.890

FY	2023
Pajamos:	$0
Bruto pelnas:	$-915 000 (0.00 %)
EPS:	$-1.890

FY	2022
Pajamos:	$0
Bruto pelnas:	$-939 000 (0.00 %)
EPS:	$-2.72

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-7.48

Financial Reports:

No articles found.

Vincerx Pharma, Inc.

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.